ライフサイエンスコーパス: extracorporeal life support

1 return of spontaneous circulation and 22% by extracorporeal life support.

2 Venoarterial or venovenous extracorporeal life support.

3 eurodevelopmental outcome after venoarterial extracorporeal life support.

4 iratory distress syndrome who were receiving extracorporeal life support.

5 timal medical therapy were implanted with an extracorporeal life support.

6 sets of cardiac surgery patients who require extracorporeal life support.

7 th mortality in children who require cardiac extracorporeal life support.

8 te hospital admission in which they received extracorporeal life support.

9 illatory ventilation, prone positioning, and extracorporeal life support.

10 Venoarterial or venovenous extracorporeal life support.

11 ilation was utilized for 1 to 17 days before extracorporeal life support.

12 nt protocols were followed before and during extracorporeal life support.

13 n infants during early and late venoarterial extracorporeal life support.

14 13 adults undergoing PLV who were receiving extracorporeal life support.

15 spiratory failure treated with lung rest and extracorporeal life support, a predicted 50% mortality r

16 Bijugular venovenous extracorporeal life support access, a pulmonary artery c

17 linical trials demonstrating the efficacy of extracorporeal life support, adult cardiopulmonary failu

18 For the first 30 mins on extracorporeal life support, all animals were ventilated

19 ts with severe respiratory failure receiving extracorporeal life support and may be associated with i

20 Patients requiring extracorporeal life support and patients initiated on co

21 mber of hospital days, continued bleeding on extracorporeal life support, and survival.

22 nd the use of recently developed systems for extracorporeal life support are required.

23 a controversial, invasive technique termed 'extracorporeal life support' as a means to provide tempo

24 Extracorporeal life support can lead to rapid reversal o

25 , adjusting for demographics, diagnosis, pre-extracorporeal life support care, extracorporeal life su

26 The extracorporeal life support cohorts were as follows: 1)

27 ), and mortality were evaluated across three extracorporeal life support cohorts.

28 at failed to demonstrate its efficacy, adult extracorporeal life support continues in limited centers

29 l ventilation and adjunctive therapies fail, extracorporeal life support continues to be used as a re

30 ing days and 11% of direct procedure-related extracorporeal life support costs.

31 cardiac catheterization laboratory (CCL) for extracorporeal life support (ECLS) and revascularization

32 Extracorporeal life support (ECLS) as a bridge to lung t

33 Critically ill neonates on extracorporeal life support (ECLS) demonstrate elevated

34 Extracorporeal life support (ECLS) during severe ARDS ma

35 Extracorporeal life support (ECLS) has become increasing

36 An artificial placenta using extracorporeal life support (ECLS) has been investigated

37 trospectively reviewed their experience with extracorporeal life support (ECLS) in 100 adult patients

38 The University of Michigan experience with extracorporeal life support (ECLS) in 1000 consecutive p

39 Extracorporeal life support (ECLS) is a means of respira

40 Survival after pediatric cardiac extracorporeal life support (ECLS) is guarded, and neuro

41 We hypothesized that extracorporeal life support (ECLS) may be an effective t

42 vous system (CNS) complications of pediatric extracorporeal life support (ECLS).

43 whose gas exchange was partially provided by extracorporeal life support (ECLS).

44 s syndrome of sufficient severity to require extracorporeal life support (ECLS).

45 nhaled nitric oxide, liquid ventilation, and extracorporeal life support (ECLS, ECMO).

46 The use of extracorporeal life support (extracorporeal membrane oxy

47 In addition, the extracorporeal life support flow rate required to mainta

48 Support International Registry who received extracorporeal life support for cardiac support between

49 mortality in pediatric patients who receive extracorporeal life support for cardiac support.

50 atabase of patients temporary implanted with extracorporeal life support for refractory arrhythmic st

51 Extracorporeal life support for severe ARDS in adults is

52 Venoarterial or venovenous extracorporeal life support for severe pulmonary failure

53 Extracorporeal life support has been implemented since t

54 Extracorporeal life support has been successful in the t

55 The use of pump-driven and pumpless extracorporeal life support has rapidly expanded and all

56 oxygenation therapy with prone ventilation, extracorporeal life support, high-frequency oscillatory

57 ccurred after a median time of 3 hours after extracorporeal life support implantation for the remaini

58 Patients' characteristics and outcomes after extracorporeal life support implantation were analyzed.

59 mproves oxygenation and reduces the need for extracorporeal life support in near-term and term newbor

60 ized and he required the rapid initiation of extracorporeal life support, in order to achieve hemodyn

61 all North American pediatric patients in the Extracorporeal Life Support International Registry who r

62 Extracorporeal life support is an invasive technique tha

63 Extracorporeal life support is extraordinary but reasona

64 Extracorporeal life support is not contraindicated in pa

65 Extracorporeal life support is used for patients with se

66 Extracorporeal life support maintains gas exchange durin

67 asurements were made early (< or = 12 hrs of extracorporeal life support, n = 10) or late (> or = 48

68 e support, n = 10) or late (> or = 48 hrs of extracorporeal life support, n = 10).

69 before extracorporeal life support, time on extracorporeal life support, number of ventilator days,

70 -hospital cardiac arrest, immediate need for extracorporeal life support or hemodialysis.

71 with chronic obstructive pulmonary disease, extracorporeal life support or hyperbaric oxygen therapy

72 We examined data from the Extracorporeal Life Support Organisation registry to ide

73 MO from 2000 to 2012 were extracted from the Extracorporeal Life Support Organization (ELSO) internat

74 The extracorporeal life support organization (ELSO) registry

75 Case reports submitted to the Extracorporeal Life Support Organization and hospital re

76 with a diagnosis of acute myocarditis in the Extracorporeal Life Support Organization database from 1

77 Data reported to Extracorporeal Life Support Organization from 350 intern

78 re from 1989 to 2013 were extracted from the Extracorporeal Life Support Organization international m

79 Data from the Extracorporeal Life Support Organization Registry and th

80 Extracorporeal Life Support Organization Registry databa

81 The Extracorporeal Life Support Organization Registry, which

82 ormed a retrospective cohort study using the Extracorporeal Life Support Organization Registry.

83 eal membrane oxygenation and included in the Extracorporeal Life Support Organization registry.

84 run for respiratory failure reported to the Extracorporeal Life Support Organization's data registry

85 Retrospective analysis of the Extracorporeal Life Support Organization's data registry

86 using E-CPR were analyzed with data from the Extracorporeal Life Support Organization, and predictors

87 rane oxygenation centers registered with the Extracorporeal Life Support Organization.

88 e recorded prospectively and reported to the Extracorporeal Life Support Organization.

89 elated with each other during early and late extracorporeal life support (p = .0001; r2 = .91).

90 thresholds and mortality in three cohorts of extracorporeal life support patients.

91 Extracorporeal life support provides life support for AR

92 s (50%) eventually died, none of them due to extracorporeal life support-related complications, but m

93 , extracorporeal life support variables, and extracorporeal life support-related complications.

94 Extracorporeal life support seems an efficient therapy f

95 Because extracorporeal life support serves only to supplement ph

96 Adult extracorporeal life support survival rates for respirato

97 Of 7,106 patients undergoing cardiac extracorporeal life support, the majority of patients we

98 led economic evaluation of hospital costs of extracorporeal life support therapy in the Netherlands s

99 rameters and systemic PaO2/FiO2 ratio before extracorporeal life support, time on extracorporeal life

100 imed at analyzing the efficacy and safety of extracorporeal life support to treat refractory arrhythm

101 ands showed that mean total hospital cost of extracorporeal life support treatment is euro 106.263 pe

102 oningen in the period 2010-2013 and received extracorporeal life support treatment.

103 life support, adult cardiopulmonary failure extracorporeal life support trials have proved less comp

104 nosis, pre-extracorporeal life support care, extracorporeal life support variables, and extracorporea

105 patients were physiologically similar before extracorporeal life support was initiated: shunt of 48 +

106 = 50 torr (</= 6.7 kPa) with an FIO2 of 1.0, extracorporeal life support was instituted.

107 Extracorporeal life support was utilized in 36 acute res

108 The costs of extracorporeal life support were differentiated in costs

109 Typical lung rest settings during extracorporeal life support were F10(2) of 0.40, peak in

110 The remaining 13 patients (50%) had extracorporeal life support withdrawn after 6.7 +/- 3.6